Publicaciones en colaboración con investigadores/as de Centro de Investigación Biomédica en Red sobre Enfermedades Hepáticas y Digestivas (18)

2023

  1. A second update on mapping the human genetic architecture of COVID-19

    Nature

2022

  1. First-in-human phase I clinical trial of a TLR4-binding DNA aptamer, ApTOLL: Safety and pharmacokinetics in healthy volunteers

    Molecular Therapy - Nucleic Acids, Vol. 28, pp. 124-135

  2. Novel genes and sex differences in COVID-19 severity

    Human molecular genetics, Vol. 31, Núm. 22, pp. 3789-3806

2021

  1. Overlapping of Independent SARS-CoV-2 Nosocomial Transmissions in a Complex Outbreak

    mSphere, Vol. 6, Núm. 4, pp. e0038921

  2. Proper Assignation of Reactivation in a COVID-19 Recurrence Initially Interpreted as a Reinfection

    The Journal of infectious diseases, Vol. 224, Núm. 5, pp. 788-792

2016

  1. European society for swallowing disorders - European union geriatric medicine society white paper: Oropharyngeal dysphagia as a geriatric syndrome

    Clinical Interventions in Aging, Vol. 11, pp. 1403-1428

2014

  1. Role of reactive oxygen species and apoptosis in Helicobacter pylori infection

    Systems Biology of Free Radicals and Antioxidants (Springer-Verlag Berlin Heidelberg), pp. 1849-1870

2013

  1. Cyclosporine A-induced apoptosis in renal tubular cells is related to oxidative damage and mitochondrial fission

    Toxicology Letters, Vol. 218, Núm. 1, pp. 30-38

  2. Helicobacter pylori inactivation and virulence gene damage using a supported sensitiser for photodynamic therapy

    European Journal of Medicinal Chemistry, Vol. 68, pp. 284-290

  3. Hepatitis B, C, and D and HIV infections among immigrants from equatorial guinea living in Spain

    American Journal of Tropical Medicine and Hygiene, Vol. 88, Núm. 4, pp. 789-794

  4. Pathogenesis of Helicobacter pylori Infection

    Helicobacter, Vol. 18, Núm. S1, pp. 12-17

2010

  1. Incidence of liver cirrhosis in HIV-infected patients with chronic hepatitis B or C in the era of highly active antiretroviral therapy

    Antiviral Therapy, Vol. 15, Núm. 6, pp. 881-886

2009

  1. Liver complications have reached a plateau as cause of hospital admission and death in HIV patients in Madrid

    AIDS Research and Human Retroviruses, Vol. 25, Núm. 4, pp. 383-385

  2. Rate and timing of hepatitis c virus relapse after a successful course of pegylated interferon plus ribavirin in hiv-infected and hiv-uninfected patients

    Clinical Infectious Diseases, Vol. 49, Núm. 9, pp. 1397-1401

  3. Vitamin E protects against the mitochondrial damage caused by cyclosporin A in LLC-PK1 cells

    Toxicology and Applied Pharmacology, Vol. 239, Núm. 3, pp. 241-250

2008

  1. Emerging drugs for hepatitis C

    Expert Opinion on Emerging Drugs, Vol. 13, Núm. 1, pp. 1-19

  2. Hepatitis B virus genotype A2 harbours an L217R polymorphism which may account for a lower response to adefovir

    Journal of Antimicrobial Chemotherapy

  3. Undetectable hepatitis C virus RNA at week 4 as predictor of sustained virological response in HIV patients with chronic hepatitis C

    AIDS, Vol. 22, Núm. 1, pp. 15-21